ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Humacyte Inc

Humacyte Inc (HUMA)

3.91
-0.01
(-0.26%)
Cerrado 16 Febrero 3:00PM
3.9398
0.0298
(0.76%)
Fuera de horario: 6:48PM

Calls

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
0.500.000.000.000.000.000.00 %00-
1.500.000.000.000.000.000.00 %00-
2.001.254.502.802.8750.000.00 %030-
2.501.251.702.101.4750.000.00 %02-
3.000.000.000.000.000.000.00 %00-
3.500.000.000.000.000.000.00 %00-
4.000.000.000.000.000.000.00 %00-
4.500.050.050.040.05-0.01-20.00 %411,63614/2/2025
5.000.000.000.000.000.000.00 %00-
5.500.050.100.050.0750.000.00 %03,341-

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Puts

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
0.500.000.000.000.000.000.00 %00-
1.500.052.550.051.300.000.00 %040-
2.000.050.350.050.200.000.00 %068-
2.500.000.000.000.000.000.00 %00-
3.000.000.000.000.000.000.00 %00-
3.500.000.000.000.000.000.00 %00-
4.000.000.000.000.000.000.00 %00-
4.500.400.850.600.6250.000.00 %01,833-
5.000.501.801.101.150.1010.00 %4570814/2/2025
5.501.351.701.101.5250.000.00 %0149-

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
430.77k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.03M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
164.82k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.4M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
489.28M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
417.31M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
INTCIntel Corporation
US$ 23.60
(-2.20%)
230.26M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
194.99M

HUMA Discussion

Ver más
FooBarAndGrill FooBarAndGrill 3 semanas hace
Humacyte and Pluristyx Partnership will aim to normalize glucose levels in diabetic patients.
https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-and-pluristyx-announce-gene-editing-partnership-support
👍️ 1
FooBarAndGrill FooBarAndGrill 4 semanas hace
Humacyte plans to file an IND for the small-diameter (3.5mm) acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG).
https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-planned-ind-filing-2025-support-first-human
👍️0
roadkilll roadkilll 4 semanas hace
In the preclinical study, the sdATEV was implanted between the aorta and right coronary artery (RCA) in five baboons to simulate a CABG procedure. Animals were followed for six months after sdATEV implantation and all sdATEVs maintained patency throughout the study. The baboon study provided an effective model for demonstrating the feasibility, mechanical durability and capacity for host-cell remodeling of the sdATEV for CABG. After implantation, the sdATEV was observed to recellularize with host cells and remodel to form a multi-layered tissue including transanastomotic neomedial tissue that effectively reduced the initial size mismatch with the RCA. The neomedial tissue observed at six months was predominantly composed of quiescent contractile smooth muscle cells under a lining of functional endothelial cells.
“Our results show that the sdATEV not only supports coronary blood flow but also host recellularization and adaptive remodeling in a challenging preclinical surgical model,” said Dr. Kirkton.
.
Functional organs from the Humacyte scaffold without autoimmune complications. No idea where the valuation would be.
👍️0
Rubraquercus Rubraquercus 4 semanas hace
In 2010, the HUMA co-founder and CEO, Dr. Laura Niklason and her colleagues were able to successfully produce an engineered rat lung that could inhale and exhale carbon dioxide.

Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine.[3][4] Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine.

en.wikipedia.org/wiki/Laura...
👍️ 1
roadkilll roadkilll 1 mes hace
Acellular Tissue Engineered Vessels - ATEV
FDA approved as safe and effective in human use

Vascular Trauma - big step in validation of ATEV and future indications

* Dialysis (AV access) - phase III study completed and proved safe and effective
* Peripheral Artery Disease - just a matter of time for approval as same technology for vascular Trauma
* Coronary Artery Bypass Grafting (CABG) - same technology works here as in vascular Trauma. Around 400,000 patients yearly.
.
This would all be low hanging fruit now that ATEV is FDA approved and are just a matter of patience. The technology has potential well beyond ATEV.
👍️0
Tiger Money Tiger Money 1 mes hace
Very nice DD
👍️0
Rubraquercus Rubraquercus 1 mes hace
1. Assigned Priority Review Designation by Secretary of Defense under Law 115-92 which is used for military purposes. mrdc.health.mil/index.cfm/a...

2. In the latest Humacyte slide deck it says "Humacyte expects DOD to stockpile for deployment to sites of conflicts.

3. The Phase 2/3 clinical data included wartime injuries in both Ukraine, and Israel the two largest warzones right now.

4. In this article from 10/16/24 CEO Laura says the Department of Defense "Sponsored some of their trials". ncchamber.com/2024/10/16/du...

5. Received RMAT designation only given to products with an "unmet need" in the field fda.gov/vaccines-blood-biol....

6. The DOD gave them $1,000,000 Grant in 2017 Through the Medical Technology Enterprise Consortium (MTEC).

7. The DOD gave them $3,400,000 Contract Award through the BAA to support the Phase 2 studies. biospace.com/humacyte-award...
👍️ 2
Rubraquercus Rubraquercus 1 mes hace
In 2010, the HUMA co-founder and CEO, Dr. Laura Niklason and her colleagues were able to successfully produce an engineered rat lung that could inhale and exhale carbon dioxide.

Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine.[3][4] Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine.

en.wikipedia.org/wiki/Laura...
👍️ 1
threebabiesbusy threebabiesbusy 2 meses hace
Humacyte price target raised to $17 from $15 at Benchmark. Looking forward to 2025. Insider buying and pt upgrades bode well for positive moves going forward.
GLTA
3
👍 1
sblzng sblzng 2 meses hace
It's gonna go .Interest is picking up and more buys than sells
👍️0
Monksdream Monksdream 2 meses hace
HUMA under $5

[color=red][/color]
👍️0
threebabiesbusy threebabiesbusy 2 meses hace
Wainwright analyst Vernon Bernardino raised the firm's price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb ...
👍️0
threebabiesbusy threebabiesbusy 2 meses hace
Let's push through the $4.80 wall!
👍️0
threebabiesbusy threebabiesbusy 2 meses hace
awww so you're out. Looks difficult for afternoon move up
👍️0
threebabiesbusy threebabiesbusy 2 meses hace
We're trading substantially below days VWAP....
👍️0
threebabiesbusy threebabiesbusy 2 meses hace
Lunch time pull back. Do you anticipate afternoon trend back up? Or do we call it one and done!
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
EXITED ON THAT PUSH BOTTOM BOUNCE
👍️0
Tiger Money Tiger Money 2 meses hace
Love having you back.  You are one of the smartest traders out there.  Unfortunately you like to be mean to less intelligent people 😝.  Anyways, how far do you think this could run?  Thanks
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
Now, reality bites.
Cash and time to ramp up.
Will vascular surgeons switch from the old and familiar?
TBD.
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
HUMA READY TO RUN AGAIN
👍️0
Tiger Money Tiger Money 2 meses hace
Finally!
👍️ 1
FooBarAndGrill FooBarAndGrill 2 meses hace
Approved
https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue
👍️ 1
FooBarAndGrill FooBarAndGrill 2 meses hace
Today is Dec 9th. Dec 9th marks 10 months since HUMA's PDUFA application.
FDA has performance goals. For regular PDUFA applications the goal is 90% within 10 months.
FDA performance goals: https://www.fda.gov/media/151712/download
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
I don't know of any. But you can roll your own using eg. Amazon Transcribe.
👍️0
tm100 tm100 2 meses hace
Is there a transcript available anywhere? Have not had any success finding a transcript
👍️0
Tiger Money Tiger Money 2 meses hace
Good news that they don't pull the plug.  This will be accepted by RFK less than a month in office 
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
The FDA is the wall. She can't say anything.
Adding that FDA has performance goals which, in this case, are not being met.
👍️0
Tiger Money Tiger Money 2 meses hace
You say ok.  So everything is moving forward with the fda still?  Thanks 
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
Webcast OK. Direct questions and direct answers.
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
Supplemental BLA. Discussed during webcast.
Replay is up. https://investors.humacyte.com/news-events/events-and-presentations
👍️0
Tiger Money Tiger Money 2 meses hace
If they are selling for any other reason than to keep it below 5%, there will be a ton of lawsuits....
👍️0
FooBarAndGrill FooBarAndGrill 2 meses hace
Stonewalled.
The family sold with the excuse to reduce below 5% holding. That's no excuse at all. They're still insiders and know exactly what's up.
👍️0
Tiger Money Tiger Money 2 meses hace
Crazy
👍️0
FooBarAndGrill FooBarAndGrill 3 meses hace
$HUMA It's all in the family:
Mr. Dougan is married to Dr. Niklason and Mr. Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Mr. Dougan may be deemed to share beneficial ownership of the securities held of record by Dr. Niklason, The Niklason Living Trust and Ayabudge LLC.
👍️0
Tiger Money Tiger Money 3 meses hace
Great color!  Time for the fda to let this run
👍️0
roadkilll roadkilll 4 meses hace
Department of Defense's priority designation is a strong tell about the future of civilian use.
"Humacyte is currently evaluating the HAV in a phase 2/3 clinical trial in vascular trauma for use as a vascular replacement to restore blood flow to a limb when saphenous veins or synthetic grafts are not feasible. The HAV has received priority designation for the treatment of vascular trauma by the United States Secretary of Defense."
Sept 22, 2023 article
.
after approval expect a quick order from DOD
👍️0
roadkilll roadkilll 4 meses hace
A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints. RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
.
FDA has awarded Humacyte for two indications.
👍️0
Monksdream Monksdream 4 meses hace
HUMA under $6
👍️0
FooBarAndGrill FooBarAndGrill 4 meses hace
Has ANYTHING changed?
August 9, 2024 “We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review.”
👍️0
Tiger Money Tiger Money 5 meses hace
This company has a lot going for it, that is for sure
👍️0
FooBarAndGrill FooBarAndGrill 5 meses hace
Humacyte up today on genuinely positive SA piece.
https://seekingalpha.com/article/4722917-humacyte-navigating-the-fda-uncertainty-and-atevs-potential
👍️0
Tiger Money Tiger Money 5 meses hace
Very nice!
👍️0
Sirpeter Sirpeter 5 meses hace
Wynn for the win...my horse is coming in
👍️0
Tiger Money Tiger Money 5 meses hace
Great to hear from you. I bought a bunch of calls for 5 cents here for he t week expiry. I can only hope Christmas comes early…
👍️0
Sirpeter Sirpeter 5 meses hace
How are ya bud...been busy...Sept sucks for stocks...only holding some WYNN calls until interest rate cuts on the 18th...have to remember to ck in once in here a while lol...hope all is good with you...talk again soon
👍️0
Tiger Money Tiger Money 5 meses hace
You still around? I have a feeling go time could be soon but fda always has em all by the balls ….
👍️0
Tiger Money Tiger Money 5 meses hace
Likey or dislikey? Just waiting on fda. Tech is there, proven and safe. A lot of limbs/lives saved in Ukraine because of humacyte
👍️0
Monksdream Monksdream 5 meses hace
HUMA under $7

👍️0
Tiger Money Tiger Money 6 meses hace
Their product is amazing. Will help so many people
👍️0
Tiger Money Tiger Money 6 meses hace
Great stuff and that is what I see too. Thanks!
👍️0

Su Consulta Reciente

Delayed Upgrade Clock